Compare United Parcel Service Inc (UPS) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
United Parcel Service Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? United Parcel Service Inc trades at $94.25 (market cap $78.52B), while Vertex Pharmaceuticals Incorporated trades at $503.25 (market cap $128.16B). The key difference: Vertex Pharmaceuticals Incorporated is the larger of the two by market cap, and United Parcel Service Inc pays a 7.11% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals — on Pluang, investors hold United Parcel Service Inc for 141 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| UPS | VRTX | |
|---|---|---|
Market Cap | $78.52B | $128.16B |
Volume | 5,159,366 | 806,603 |
Sector | Industrials | Health |
52-Week High | $120.00 | $557.96 |
52-Week Low | $82.87 | $407.37 |
Typical Hold Time | 141 Days | 120 Days |
Enterprise Value | $102.54B | $122.29B |
Dividend Yield | 7.11% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
UPS trades at $94.11, up 1.07% with bearish technical signals but strong fundamentals including a 17.15 P/E ratio and 29.66% ROE. The company has beaten earnings estimates for three consecutive quarters, though revenue has declined from $100.3B in 2022 to $88.7B in 2025. Recent developments include the UPS Secure Commerce platform launch and TikTok Shop partnership, while analysts maintain a $118.67 consensus price target despite near-term margin pressures.
UPS presents a value opportunity with attractive valuation metrics and consistent earnings beats, though declining revenue and competitive pressures from Amazon pose challenges. The 7% dividend yield provides income support, but investors should monitor domestic package volume trends and margin sustainability given recent analyst downgrades and bearish technical indicators.
Vertex Pharmaceuticals (VRTX) trades at $503.25, showing modest daily gains of 0.16%. The stock faces bearish technical signals with mixed earnings performance, missing Q4 2025 and Q2 2026 EPS estimates but beating Q1 2026. Strong fundamentals include 86% gross margins and 35% net income margins, with revenue projected to grow from $12B to $12.6B in 2026. Recent positive Phase II data for kidney disease drug inaxaplin highlights pipeline progress.
Outlook remains positive with 84% analyst buy ratings and $573 consensus target offering 14% upside. Key risks include reliance on cystic fibrosis franchise and competitive pressures. Earnings consistency and pipeline execution are critical for sustained growth amid current technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About United Parcel Service Inc
United Parcel Service, Inc. (UPS) delivers packages and documents throughout the United States and in other countries and territories. The Company also provides global supply chain services and less-than-truckload transportation, primarily in the US UPS's business consists of integrated air and ground pick-up and delivery network
Read more on UPS →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
